Ogawa Kohei, Kamimura Kenya, Watanabe Yukari, Motai Yosuke, Kumaki Daisuke, Seki Ryoya, Sakamaki Akira, Abe Satoshi, Kawai Hirokazu, Suda Takeshi, Yamagiwa Satoshi, Terai Shuji
Kohei Ogawa, Kenya Kamimura, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai, Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.
World J Clin Cases. 2017 Jun 16;5(6):238-246. doi: 10.12998/wjcc.v5.i6.238.
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third highest cause of cancer-associated mortality worldwide. The treatment of HCC is complicated by its variable biological behavior and the frequent coexistence of chronic liver disease, particularly cirrhosis. To date, multiple treatment modalities have been developed according to the stage of the tumor and the hepatic functional reserve, including transarterial treatments such as transarterial chemoembolization, transarterial oily chemoembolization (TOCE), and hepatic arterial infusion chemotherapy (HAIC). We conducted a phase I and II study of the combination therapy with double platinum agents, miriplatin and cisplatin, and confirmed its safety and efficacy. Here, we describe two cases of unresectable HCC who were successfully treated by miriplatin-TOCE/cisplatin-HAIC combination therapy, resulting in complete responses with no significant adverse events. This report will provide that the combination therapy can be the therapeutic option for HCC patients in the advanced stage.
肝细胞癌（HCC）是最常见的癌症之一，也是全球癌症相关死亡率的第三大原因。HCC的治疗因其生物学行为多变以及慢性肝病（尤其是肝硬化）的频繁共存而变得复杂。迄今为止，已根据肿瘤分期和肝功能储备开发了多种治疗方式，包括经动脉治疗，如经动脉化疗栓塞、经动脉油性化疗栓塞（TOCE）和肝动脉灌注化疗（HAIC）。我们进行了一项关于米铂和顺铂这两种双铂类药物联合治疗的I期和II期研究，并证实了其安全性和有效性。在此，我们描述了两例不可切除HCC患者，他们通过米铂-TOCE/顺铂-HAIC联合治疗成功治愈，实现了完全缓解且无明显不良事件。本报告将表明联合治疗可成为晚期HCC患者的治疗选择。
